A study published in the journal Neurology claims to have confirmed the usefulness of a biomarker in blood to diagnose Alzheimer's disease without the need for other tests.
A few weeks ago, a press release from the Biogen and Eisai companies reported significant results from their lecanemab antibody for the treatment of early-stage Alzheimer's. The data from the phase 3 trial are now published in the New England Journal of Medicine, coinciding with the CTAD conference on Alzheimer's disease clinical trials in San Francisco. Data from the phase 3 clinical trial are now published in the New England Journal of Medicine, coinciding with the 15th CTAD Alzheimer's disease clinical trials conference in San Francisco.
People with Down syndrome are at high risk of developing dementia very similar to that caused by Alzheimer's disease. A study published in the journal PNAS has found that in these people, as had been observed in "classic" Alzheimer's, the characteristic proteins of the disease have prion-like features.
Scientists have analysed data on 7.1 million common DNA variants (alterations in the standard sequence) in people with and without Alzheimer's disease. The results, published in PLOS Genetics, have helped them to develop a method that can predict the risk of suffering from this neurodegenerative disease, depending on the DNA variants that a person has and before presenting symptoms.
Science magazine has published a report revealing multiple indications of fraud in one of the most cited publications on Alzheimer's disease. We explain what it means for the science that studies this disease.
A study published today in the Journal of Neurology Neurosurgery & Psychiatry claims that some drugs used to treat attention deficit hyperactivity disorder (ADHD) may also help with some symptoms of Alzheimer's disease.